

Author index

Volume 28 (1995)

- Agarwal, M., see Hughes, P.F. 28, 73
 Altuğ, T., see Kaymaz, A.A. 28, 201
 Amano, K., K. Yokono, Y. Hasegawa, T. Taki, Y. Tominaga, R. Yoneda, M. Nagata, M. Kasuga, A novel function of islet-derived CD8⁺T cells in initiating and developing autoimmune insulin-dependent diabetes mellitus in non-obese diabetic (NOD) mice 28, 161
 Andersson, P.-O., see Hörnquist, J.O. 28, 63
 Andreani, D., see Sensi, M. 28, 9
 Aragaki, S., see Kayashima, T. 28, 119
 Araki, E., see Ohkubo, Y. 28, 103
 Asahina, T., see Suzuki, Y. 28, 147
 Atsumi, Y., see Suzuki, Y. 28, 147
- Bollani, E., see d'Annunzio, G. 28, 57
 Boulton, A.J.M., see Young, C.A. 28, 47
 Büyükdevrim, A.S., see Kaymaz, A.A. 28, 201
- Chang, F.-Y., M.-F. Shaio, Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus 28, 137
 Chase, H.P., see Garg, S.K. 28, 51
 Chen, J.-w., see Wang, H. 28, 1
 Colagiuri, S., L.L. Marsden, V. Naidu, L. Taylor, The use of orthotic devices to correct plantar callus in people with diabetes 28, 29
 Colette, C., see Rodier, M. 28, 19
 Coronel, G.A., see Coscelli, C. 28, 173
 Coscelli, C., S. Lostia, M. Lunetta, I. Nosari, G.A. Coronel, Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old 28, 173
 Crastes de Paulet, A., see Rodier, M. 28, 19
 Cristina, A., see Sensi, M. 28, 9
- d'Annunzio, G., A. Moglia, C. Zandrini, E. Bollani, L. Vitali, P. Pessino, A. Scaramuzza, G. Lanzi, R. Lorini, Central motor conduction time in children and adolescents with insulin-dependent diabetes mellitus (IDDM) 28, 57
 Di Mario, U., see Sensi, M. 28, 9
- Eto, M., see Itoh, H. 28, 89
- Fabris, S., see Thorburn, A. 28, 127
 Fukawa, E., see Hirano, F. 28, 151
 Furuyoshi, N., see Ohkubo, Y. 28, 103
- Garg, S.K., H.P. Chase, H. Shapiro, S. Harris, I.M. Osberg, Exercise versus overnight albumin excretion rates in subjects with type 1 diabetes 28, 51
 Gandy, A., see Wilson, B.E. 28, 179
 Goto, Y., K. Yamada, T. Ohyama, T. Matsuo, H. Odaka, H. Ikeda, An α -glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans 28, 81
 Gouzes, Ch., see Rodier, M. 28, 19
 Grazia De Rossi, M., see Sensi, M. 28, 9
 Greene, R.J., see Sussman, K.E. 28, 149
- Harris, S., see Garg, S.K. 28, 51
 Hasegawa, Y., see Amano, K. 28, 161
 Hirano, F., H. Tanaka, K. Okamoto, Y. Makino, M. Inaba, Y. Nomura, E. Fukawa, T. Miura, T. Tani, I. Makino, Natural course of diabetic peripheral neuropathy in spontaneous-onset diabetic Chinese hamsters 28, 151
 Hörnquist, J.O., A. Wikby, U. Stenström, P.-O. Andersson, Change in quality of life along with type 1 diabetes 28, 63
 Hoshi, M., see Izumi, K. 28, 185
 Hosokawa, K., see Suzuki, Y. 28, 147
 Hughes, P.F., M. Agarwal, P. Newman, J. Morrison, Screening for gestational diabetes in a multi-ethnic population 28, 73
- Ikeda, H., see Goto, Y. 28, 81
 Ikeda, Y., see Tsuruoka, A. 28, 191
 Inaba, M., see Hirano, F. 28, 151
 Isami, S., see Ohkubo, Y. 28, 103
 Isshiki, G., see Izumi, K. 28, 185
 Isshiki, G., see Tsuruoka, A. 28, 191
 Itoh, H., M. Yoneda, K. Tamori, Y. Miyamoto, A. Morikawa, M. Eto, I. Makino, Rapid gastric emptying and pathological changes of vagus nerve in the spontaneously diabetic Chinese hamster 28, 89

- Izumi, K., M. Hoshi, S. Kuno, G. Okuno, R. Kawamori, G. Isshiki, A. Sasaki, Glycemic control, growth and complications in children with insulin-dependent diabetes mellitus — a study of children enrolled in a Summer camp program for diabetics in Kinki district, Japan 28, 185
- Kameoka, K., see Kitaoka, H. 28, 207
- Kasuga, M., see Amano, K. 28, 161
- Katagiri, H., see Kitaoka, H. 28, 207
- Kawamori, R., see Izumi, K. 28, 185
- Kayashima, T., K. Yamaguchi, Y. Konno, H. Nanimatsu, S. Aragaki, M. Shichiri, Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients 28, 119
- Kaymaz, A.A., H. Tan, T. Altu*g, A.S. Büyükdevrim, The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats 28, 201
- Kishikawa, H., see Ohkubo, Y. 28, 103
- Kitaoka, H., K. Kameoka, Y. Suzuki, E. Sasaki, M. Majima, K. Takada, H. Katagiri, Y. Oka, N. Ohsawa, A patient with diabetes mellitus, cardiomyopathy, and a mitochondrial gene mutation: confirmation of a gene mutation in cardiac muscle 28, 207
- Kojima, Y., see Ohkubo, Y. 28, 103
- Konno, Y., see Kayashima, T. 28, 119
- Kumar, S., see Young, C.A. 28, 47
- Kuno, S., see Izumi, K. 28, 185
- Lanzi, G., see d'Annunzio, G. 28, 57
- Litchfield, A., see Thorburn, A. 28, 127
- Lorini, R., see d'Annunzio, G. 28, 57
- Lostia, S., see Coscelli, C. 28, 173
- Lunetta, M., see Coscelli, C. 28, 173
- Majima, M., see Kitaoka, H. 28, 207
- Makino, I., see Hirano, F. 28, 151
- Makino, I., see Itoh, H. 28, 89
- Makino, Y., see Hirano, F. 28, 151
- Marsden, L.L., see Colagiuri, S. 28, 29
- Martinez, D., see Neumann, C. 28, 97
- Matsuba, I., see Tsuruoka, A. 28, 191
- Matsuo, T., see Goto, Y. 28, 81
- Matsuoka, K., see Suzuki, Y. 28, 147
- Michel, F., see Rodier, M. 28, 19
- Miura, T., see Hirano, F. 28, 151
- Miyamoto, Y., see Itoh, H. 28, 89
- Miyata, T., see Ohkubo, Y. 28, 103
- Moglia, A., see d'Annunzio, G. 28, 57
- Monnier, L., see Rodier, M. 28, 19
- Morano, S., see Sensi, M. 28, 9
- Mori, M., see Shimizu, H. 28, 35
- Morikawa, A., see Itoh, H. 28, 89
- Morrison, J., see Hughes, P.F. 28, 73
- Motoyoshi, S., see Ohkubo, Y. 28, 103
- Nagata, M., see Amano, K. 28, 161
- Nagataki, S., see Tsuruoka, A. 28, 191
- Naidu, V., see Colagiuri, S. 28, 29
- Nakamura, S., see Suzuki, Y. 28, 147
- Nanimatsu, H., see Kayashima, T. 28, 119
- Neumann, C., D. Martinez, H. Schmid, Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy 28, 97
- Newman, P., see Hughes, P.F. 28, 73
- Nomura, Y., see Hirano, F. 28, 151
- Nosari, I., see Coscelli, C. 28, 173
- Odaka, H., see Goto, Y. 28, 81
- Ohkubo, Y., H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furuyoshi, M. Shichiri, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study 28, 103
- Ohsawa, N., see Kitaoka, H. 28, 207
- Ohtani, K.-i., see Shimizu, H. 28, 35
- Ohyama, T., see Goto, Y. 28, 81
- Oka, Y., see Kitaoka, H. 28, 207
- Okamoto, K., see Hirano, F. 28, 151
- Okuno, G., see Izumi, K. 28, 185
- Osberg, I.M., see Garg, S.K. 28, 51
- Paganini, J.M., see Sussman, K.E. 28, 149
- Pessino, P., see d'Annunzio, G. 28, 57
- Petrucci, A.F.G., see Sensi, M. 28, 9
- Pozzessere, G., see Sensi, M. 28, 9
- Pricci, F., see Sensi, M. 28, 9
- Proietto, J., see Thorburn, A. 28, 127
- Pugliese, G., see Sensi, M. 28, 9
- Ramachandran, A., see Vijay Viswanathan, V. 28, 41
- Rodier, M., C. Colette, Ch. Gouzes, F. Michel, A. Crastes de Paulet, L. Monnier, Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents 28, 19
- Sasaki, A., see Izumi, K. 28, 185
- Sasaki, E., see Kitaoka, H. 28, 207
- Sato, N., see Shimizu, H. 28, 35
- Scaramuzza, A., see d'Annunzio, G. 28, 57
- Schmid, H., see Neumann, C. 28, 97
- Sensi, M., F. Pricci, G. Pugliese, M. Grazia De Rossi, A.F.G. Petrucci, A. Cristina, S. Morano, G. Pozzessere, E. Valle, D. Andreani, U. Di Mario, Role of advanced glycation end-products (AGE) in late diabetic complications 28, 9
- Shaio, M.-F., see , 28, 137
- Shapiro, H., see Garg, S.K. 28, 51
- Shichiri, M., see Kayashima, T. 28, 119
- Shichiri, M., see Ohkubo, Y. 28, 103
- Shimizu, H., K.-i. Ohtani, Y. Tanaka, N. Sato, M. Mori, Y. Shimomura, Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients 28, 35

- Shimomura, Y., see Shimizu, H. 28, 35
 Snehalatha, C., see Vijay Viswanathan, V. 28, 41
 Stenström, U., see Hörnquist, J.O. 28, 63
 Sussman, K.E., R.J. Greene, J.M. Paganini, Quality assessment and improvement in diabetes health care — an issue now and for the future 28, 149
 Suzuki, Y., M. Taniyama, S. Nakamura, Y. Tanaka, T. Asahina, Y. Atsumi, K. Hosokawa, K. Matsuoka, Atonic bladder in diabetes mellitus due to 3243 bp mitochondrial tRNA^{Leu(UUR)} mutation 28, 147
 Suzuki, Y., see Kitaoka, H. 28, 207

 Takada, K., see Kitaoka, H. 28, 207
 Taki, T., see Amano, K. 28, 161
 Tamori, K., see Itoh, H. 28, 89
 Tan, H., see Kaymaz, A.A. 28, 201
 Tanaka, H., see Hirano, F. 28, 151
 Tanaka, Y., see Shimizu, H. 28, 35
 Tanaka, Y., see Suzuki, Y. 28, 147
 Tani, T., see Hirano, F. 28, 151
 Taniyama, M., see Suzuki, Y. 28, 147
 Taylor, L., see Colagiuri, S. 28, 29
 Thorburn, A., A. Litchfield, S. Fabris, J. Proietto, Abnormal transient rise in hepatic glucose production after oral glucose in non-insulin-dependent diabetic subjects 28, 127
 Tominaga, Y., see Amano, K. 28, 161
 Toyota, T., see Tsuruoka, A. 28, 191
 Tsuruoka, A., I. Matsuba, T. Toyota, G. Isshiki, S. Nagataki, Y. Ikeda, Antibodies to GAD in Japanese diabetic patients: a multicenter study 28, 191

 Valle, E., see Sensi, M. 28, 9
 Vijay Viswanathan, V., C. Snehalatha, A. Ramachandran, M. Viswanathan, Proteinuria in NIDDM in South India: analysis of predictive factors 28, 41
 Viswanathan, M., see Vijay Viswanathan, V. 28, 41
 Vitali, L., see d'Annunzio, G. 28, 57

 Wang, H., Z.-b. Zhang, R.-r. Wen, J.-w. Chen, Experimental and clinical studies on the reduction of erythrocyte sorbitol-glucose ratios by ascorbic acid in diabetes mellitus 28, 1
 Wen, R.-r., see Wang, H. 28, 1
 Wikby, A., see Hörnquist, J.O. 28, 63
 Wilson, B.E., A. Gondy, Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects 28, 179

 Yamada, K., see Goto, Y. 28, 81
 Yamaguchi, K., see Kayashima, T. 28, 119
 Yokono, K., see Amano, K. 28, 161
 Yoneda, M., see Itoh, H. 28, 89
 Yoneda, R., see Amano, K. 28, 161
 Young, C.A., S. Kumar, M.J. Young, A.J.M. Boulton, Excess maternal history of diabetes in Caucasian and Afro- origin non-insulin-dependent diabetic patients suggests dominant maternal factors in disease transmission 28, 47
 Young, M.J., see Young, C.A. 28, 47

 Zandrini, C., see d'Annunzio, G. 28, 57
 Zhang, Z.-b., see Wang, H. 28, 1

1. The first part of the paper is devoted to a general discussion of the problem.

2. The second part is devoted to a detailed analysis of the case of a single particle.

3. The third part is devoted to a detailed analysis of the case of a system of particles.

4. The fourth part is devoted to a detailed analysis of the case of a system of particles.

5. The fifth part is devoted to a detailed analysis of the case of a system of particles.

6. The sixth part is devoted to a detailed analysis of the case of a system of particles.

7. The seventh part is devoted to a detailed analysis of the case of a system of particles.

8. The eighth part is devoted to a detailed analysis of the case of a system of particles.

9. The ninth part is devoted to a detailed analysis of the case of a system of particles.

10. The tenth part is devoted to a detailed analysis of the case of a system of particles.

11. The eleventh part is devoted to a detailed analysis of the case of a system of particles.

12. The twelfth part is devoted to a detailed analysis of the case of a system of particles.

13. The thirteenth part is devoted to a detailed analysis of the case of a system of particles.

14. The fourteenth part is devoted to a detailed analysis of the case of a system of particles.

15. The fifteenth part is devoted to a detailed analysis of the case of a system of particles.

16. The sixteenth part is devoted to a detailed analysis of the case of a system of particles.

17. The seventeenth part is devoted to a detailed analysis of the case of a system of particles.

18. The eighteenth part is devoted to a detailed analysis of the case of a system of particles.

19. The nineteenth part is devoted to a detailed analysis of the case of a system of particles.

20. The twentieth part is devoted to a detailed analysis of the case of a system of particles.

21. The twenty-first part is devoted to a detailed analysis of the case of a system of particles.

22. The twenty-second part is devoted to a detailed analysis of the case of a system of particles.

23. The twenty-third part is devoted to a detailed analysis of the case of a system of particles.

24. The twenty-fourth part is devoted to a detailed analysis of the case of a system of particles.

25. The twenty-fifth part is devoted to a detailed analysis of the case of a system of particles.

26. The twenty-sixth part is devoted to a detailed analysis of the case of a system of particles.

27. The twenty-seventh part is devoted to a detailed analysis of the case of a system of particles.

28. The twenty-eighth part is devoted to a detailed analysis of the case of a system of particles.

29. The twenty-ninth part is devoted to a detailed analysis of the case of a system of particles.

30. The thirtieth part is devoted to a detailed analysis of the case of a system of particles.

31. The thirty-first part is devoted to a detailed analysis of the case of a system of particles.

32. The thirty-second part is devoted to a detailed analysis of the case of a system of particles.

33. The thirty-third part is devoted to a detailed analysis of the case of a system of particles.

34. The thirty-fourth part is devoted to a detailed analysis of the case of a system of particles.

35. The thirty-fifth part is devoted to a detailed analysis of the case of a system of particles.

36. The thirty-sixth part is devoted to a detailed analysis of the case of a system of particles.

37. The thirty-seventh part is devoted to a detailed analysis of the case of a system of particles.

38. The thirty-eighth part is devoted to a detailed analysis of the case of a system of particles.

39. The thirty-ninth part is devoted to a detailed analysis of the case of a system of particles.

40. The fortieth part is devoted to a detailed analysis of the case of a system of particles.



Subject index

Volume 28 (1995)

- α -glucosidase inhibitor;** Hyperglycemia; Breath hydrogen; Diabetes 28, 81
- Adoptive transfer of diabetes;** Non-obese diabetic (NOD) mice; T cell hybridoma; CD4⁺T cells; CD8⁺T cells 28, 161
- Advanced glycation end-products (AGE);** Maillard's reaction; Aging; Proteins; Senescence; Diabetic complications 28, 9
- Adverse pregnancy outcome;** Screening; Gestational diabetes mellitus; Multi-ethnic population 28, 73
- Aging;** Maillard's reaction; Advanced glycation end-products (AGE); Proteins; Senescence; Diabetic complications 28, 9
- Albumin excretion rate;** Exercise albumin excretion rate; Insulin-dependent (type 1) diabetes mellitus; Microalbuminuria; Overnight albumin excretion rate 28, 51
- Albuminuria;** Non-insulin dependent diabetes mellitus; *N*-Acetyl-D-glucosaminidase; β_2 -Microglobulin; Eicosapentaenoic acid 28, 35
- Antibodies to glutamic acid decarboxylase;** Radioimmunoassay; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus 28, 191
- Ascorbic acid;** Human; Erythrocyte sorbitol; Erythrocyte glucose; Diabetes; Polyol pathway 28, 1
- Asians;** Non-insulin-dependent diabetes mellitus; Maternal history; Family history 28, 47
- Atonic bladder;** Mitochondrial tRNA mutation; Mitochondrial diabetes mellitus; Bladder dysfunction; Post-treatment neuropathy 28, 147
- Autonomic neuropathy;** Gastric emptying; Vagus nerve; Spontaneously diabetic Chinese hamster 28, 89
- β_2 -Microglobulin;** Non-insulin dependent diabetes mellitus; Albuminuria; *N*-Acetyl-D-glucosaminidase; Eicosapentaenoic acid 28, 35
- Bladder dysfunction;** Mitochondrial tRNA mutation; Mitochondrial diabetes mellitus; Atonic bladder; Post-treatment neuropathy 28, 147
- Blood glucose control;** Elderly diabetic patient; Insulin injection pen; Compliance 28, 173
- Blood pressure;** NIDDM; Nephropathy; Proteinuria; Creatinine clearance 28, 41
- Breath hydrogen;** α -glucosidase inhibitor; Hyperglycemia; Diabetes 28, 81
- Calcium channel blockers;** Diabetes mellitus; Streptozotocin; Metabolic control 28, 201
- Cardiomyopathy;** Diabetes mellitus; Mitochondrial DNA mutation; Deafness; MELAS 28, 207
- Cardiovascular risk;** Chromium; Insulin resistance 28, 179
- CD4⁺T cells;** Non-obese diabetic (NOD) mice; T cell hybridoma; Adoptive transfer of diabetes; CD8⁺T cells 28, 161
- CD8⁺T cells;** Non-obese diabetic (NOD) mice; T cell hybridoma; Adoptive transfer of diabetes; CD4⁺T cells 28, 161
- Central nervous system;** Insulin-dependent diabetes mellitus; Diabetic neuropathy; Neurophysiological tests 28, 57
- Chromium;** Cardiovascular risk; Insulin resistance 28, 179
- Compliance;** Elderly diabetic patient; Insulin injection pen; Blood glucose control 28, 173
- Control of respiration;** Severe autonomic neuropathy; Nocturnal oximetry; Desaturation episodes 28, 97
- Coping and defence mechanisms;** Type 1 diabetes; Quality of life; Retro and prospective longitudinal studies 28, 63
- Creatinine clearance;** NIDDM; Nephropathy; Proteinuria; Blood pressure 28, 41
- Cytokine production;** Non-insulin-dependent diabetes; Lymphocyte proliferation; Mononuclear cells; Interleukin-2 receptor 28, 137
- Deafness;** Diabetes mellitus; Mitochondrial DNA mutation; Cardiomyopathy; MELAS 28, 207
- Desaturation episodes;** Severe autonomic neuropathy; Nocturnal oximetry; Control of respiration 28, 97
- Diabetes;** α -glucosidase inhibitor; Hyperglycemia; Breath hydrogen 28, 81
- Diabetes;** Human; Erythrocyte sorbitol; Erythrocyte glucose; Ascorbic acid; Polyol pathway 28, 1
- Diabetes;** Plantar callus; Rigid orthoses 28, 29
- Diabetes mellitus;** Calcium channel blockers; Streptozotocin; Metabolic control 28, 201
- Diabetes mellitus;** Mitochondrial DNA mutation; Cardiomyopathy; Deafness; MELAS 28, 207
- Diabetes mellitus;** Neuropathy; Polyol; Pathology; Nerve conduction velocity 28, 151

- Diabetic complications;** Maillard's reaction; Advanced glycation end-products (AGE); Aging; Proteins; Senescence 28, 9
- Diabetic neuropathy;** Insulin-dependent diabetes mellitus; Central nervous system; Neurophysiological tests 28, 57
- Diabetic retinopathy;** Insulin-dependent diabetes mellitus (IDDM); Summer camp program for diabetic children; HbA_{1c}; Growth 28, 185
- Eicosapentaenoic acid;** Non-insulin dependent diabetes mellitus; Albuminuria; N-Acetyl-D-glucosaminidase; β_2 -Microglobulin 28, 35
- Elderly diabetic patient;** Insulin injection pen; Blood glucose control; Compliance 28, 173
- Erythrocyte glucose;** Human; Erythrocyte sorbitol; Ascorbic acid; Diabetes; Polyol pathway 28, 1
- Erythrocyte sorbitol;** Human; Erythrocyte glucose; Ascorbic acid; Diabetes; Polyol pathway 28, 1
- Exercise albumin excretion rate;** Albumin excretion rate; Insulin-dependent (type 1) diabetes mellitus; Microalbuminuria; Overnight albumin excretion rate 28, 51
- Family history;** Non-insulin-dependent diabetes mellitus; Asians; Maternal history 28, 47
- Fatty acid;** Non-insulin-dependent diabetes; Insulin treatment; Metabolic control 28, 19
- Gastric emptying;** Vagus nerve; Autonomic neuropathy; Spontaneously diabetic Chinese hamster 28, 89
- Gestational diabetes mellitus;** Screening; Multi-ethnic population; Adverse pregnancy outcome 28, 73
- Glucose kinetics;** Hepatic glucose production; Non-insulin-dependent diabetes; Plasma glucagon; Glucose turnover 28, 127
- Glucose turnover;** Hepatic glucose production; Non-insulin-dependent diabetes; Plasma glucagon; Glucose kinetics 28, 127
- Glycemic threshold;** Non-insulin-dependent diabetes mellitus; Microvascular complications; Intensive glycemic control; Multiple insulin injection treatment 28, 103
- Growth;** Insulin-dependent diabetes mellitus (IDDM); Summer camp program for diabetic children; HbA_{1c}; Diabetic retinopathy 28, 185
- HbA_{1c};** Insulin-dependent diabetes mellitus (IDDM); Summer camp program for diabetic children; Growth; Diabetic retinopathy 28, 185
- Hepatic glucose production;** Non-insulin-dependent diabetes; Plasma glucagon; Glucose turnover; Glucose kinetics 28, 127
- Human;** Erythrocyte sorbitol; Erythrocyte glucose; Ascorbic acid; Diabetes; Polyol pathway 28, 1
- Hyperglycemia;** α -glucosidase inhibitor; Breath hydrogen; Diabetes 28, 81
- Insulin injection pen;** Elderly diabetic patient; Blood glucose control; Compliance 28, 173
- Insulin resistance;** Chromium; Cardiovascular risk 28, 179
- Insulin therapy;** Withdrawal of insulin; Non-obese NIDDM; Proliferative retinopathy 28, 119
- Insulin treatment;** Non-insulin-dependent diabetes; Metabolic control; Fatty acid 28, 19
- Insulin-dependent (type 1) diabetes mellitus;** Albumin excretion rate; Exercise albumin excretion rate; Microalbuminuria; Overnight albumin excretion rate 28, 51
- Insulin-dependent diabetes mellitus (IDDM);** Summer camp program for diabetic children; HbA_{1c}; Growth; Diabetic retinopathy 28, 185
- Insulin-dependent diabetes mellitus;** Antibodies to glutamic acid decarboxylase; Radioimmunoassay; Non-insulin-dependent diabetes mellitus 28, 191
- Insulin-dependent diabetes mellitus;** Diabetic neuropathy; Central nervous system; Neurophysiological tests 28, 57
- Intensive glycemic control;** Non-insulin-dependent diabetes mellitus; Microvascular complications; Multiple insulin injection treatment; Glycemic threshold 28, 103
- Interleukin-2 receptor;** Non-insulin-dependent diabetes; Lymphocyte proliferation; Mononuclear cells; Cytokine production 28, 137
- Lymphocyte proliferation;** Non-insulin-dependent diabetes; Mononuclear cells; Interleukin-2 receptor; Cytokine production 28, 137
- Maillard's reaction;** Advanced glycation end-products (AGE); Aging; Proteins; Senescence; Diabetic complications 28, 9
- Maternal history;** Non-insulin-dependent diabetes mellitus; Asians; Family history 28, 47
- MELAS;** Diabetes mellitus; Mitochondrial DNA mutation; Cardiomyopathy; Deafness 28, 207
- Metabolic control;** Calcium channel blockers; Diabetes mellitus; Streptozotocin 28, 201
- Metabolic control;** Non-insulin-dependent diabetes; Insulin treatment; Fatty acid 28, 19
- Microalbuminuria;** Albumin excretion rate; Exercise albumin excretion rate; Insulin-dependent (type 1) diabetes mellitus; Overnight albumin excretion rate 28, 51
- Microvascular complications;** Non-insulin-dependent diabetes mellitus; Intensive glycemic control; Multiple insulin injection treatment; Glycemic threshold 28, 103
- Mitochondrial diabetes mellitus;** Mitochondrial tRNA mutation; Bladder dysfunction; Atonic bladder; Post-treatment neuropathy 28, 147
- Mitochondrial DNA mutation;** Diabetes mellitus; Cardiomyopathy; Deafness; MELAS 28, 207
- Mitochondrial tRNA mutation;** Mitochondrial diabetes mellitus; Bladder dysfunction; Atonic bladder; Post-treatment neuropathy 28, 147
- Mononuclear cells;** Non-insulin-dependent diabetes; Lymphocyte proliferation; Interleukin-2 receptor; Cytokine production 28, 137
- Multi-ethnic population;** Screening; Gestational diabetes mellitus; Adverse pregnancy outcome 28, 73
- Multiple insulin injection treatment;** Non-insulin-dependent

- diabetes mellitus; Microvascular complications; Intensive glycemic control; Glycemic threshold 28, 103
- N-Acetyl-D-glucosaminidase**; Non-insulin dependent diabetes mellitus; Albuminuria; β_2 -Microglobulin; Eicosapentaenoic acid 28, 35
- Nephropathy**; NIDDM; Proteinuria; Creatinine clearance; Blood pressure 28, 41
- Nerve conduction velocity**; Neuropathy; Diabetes mellitus; Polyol; Pathology 28, 151
- Neuropathy**; Diabetes mellitus; Polyol; Pathology; Nerve conduction velocity 28, 151
- Neurophysiological tests**; Insulin-dependent diabetes mellitus; Diabetic neuropathy; Central nervous system 28, 57
- NIDDM**; Nephropathy; Proteinuria; Creatinine clearance; Blood pressure 28, 41
- Nocturnal oximetry**; Severe autonomic neuropathy; Desaturation episodes; Control of respiration 28, 97
- Non-insulin dependent diabetes mellitus**; Albuminuria; N-Acetyl-D-glucosaminidase; β_2 -Microglobulin; Eicosapentaenoic acid 28, 35
- Non-insulin-dependent diabetes**; Hepatic glucose production; Plasma glucagon; Glucose turnover; Glucose kinetics 28, 127
- Non-insulin-dependent diabetes**; Insulin treatment; Metabolic control; Fatty acid 28, 19
- Non-insulin-dependent diabetes**; Lymphocyte proliferation; Mononuclear cells; Interleukin-2 receptor; Cytokine production 28, 137
- Non-insulin-dependent diabetes mellitus**; Antibodies to glutamic acid decarboxylase; Radioimmunoassay; Insulin-dependent diabetes mellitus 28, 191
- Non-insulin-dependent diabetes mellitus**; Asians; Maternal history; Family history 28, 47
- Non-insulin-dependent diabetes mellitus**; Microvascular complications; Intensive glycemic control; Multiple insulin injection treatment; Glycemic threshold 28, 103
- Non-obese diabetic (NOD) mice**; T cell hybridoma; Adoptive transfer of diabetes; CD4⁺T cells; CD8⁺T cells 28, 161
- Non-obese NIDDM**; Insulin therapy; Withdrawal of insulin; Proliferative retinopathy 28, 119
- Overnight albumin excretion rate**; Albumin excretion rate; Exercise albumin excretion rate; Insulin-dependent (type 1) diabetes mellitus; Microalbuminuria 28, 51
- Pathology**; Neuropathy; Diabetes mellitus; Polyol; Nerve conduction velocity 28, 151
- Plantar callus**; Rigid orthoses; Diabetes 28, 29
- Plasma glucagon**; Hepatic glucose production; Non-insulin-dependent diabetes; Glucose turnover; Glucose kinetics 28, 127
- Polyol**; Neuropathy; Diabetes mellitus; Pathology; Nerve conduction velocity 28, 151
- Polyol pathway**; Human; Erythrocyte sorbitol; Erythrocyte glucose; Ascorbic acid; Diabetes 28, 1
- Post-treatment neuropathy**; Mitochondrial tRNA mutation; Mitochondrial diabetes mellitus; Bladder dysfunction; Atonic bladder 28, 147
- Proliferative retinopathy**; Insulin therapy; Withdrawal of insulin; Non-obese NIDDM 28, 119
- Proteins**; Maillard's reaction; Advanced glycation end-products (AGE); Aging; Senescence; Diabetic complications 28, 9
- Proteinuria**; NIDDM; Nephropathy; Creatinine clearance; Blood pressure 28, 41
- Quality of life**; Type 1 diabetes; Coping and defence mechanisms; Retro and prospective longitudinal studies 28, 63
- Radioimmunoassay**; Antibodies to glutamic acid decarboxylase; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus 28, 191
- Retro and prospective longitudinal studies**; Type 1 diabetes; Quality of life; Coping and defence mechanisms 28, 63
- Rigid orthoses**; Plantar callus; Diabetes 28, 29
- Screening**; Gestational diabetes mellitus; Multi-ethnic population; Adverse pregnancy outcome 28, 73
- Senescence**; Maillard's reaction; Advanced glycation end-products (AGE); Aging; Proteins; Diabetic complications 28, 9
- Severe autonomic neuropathy**; Nocturnal oximetry; Desaturation episodes; Control of respiration 28, 97
- Spontaneously diabetic Chinese hamster**; Gastric emptying; Vagus nerve; Autonomic neuropathy 28, 89
- Streptozotocin**; Calcium channel blockers; Diabetes mellitus; Metabolic control 28, 201
- Summer camp program for diabetic children**; Insulin-dependent diabetes mellitus (IDDM); HbA_{1c}; Growth; Diabetic retinopathy 28, 185
- T cell hybridoma**; Non-obese diabetic (NOD) mice; Adoptive transfer of diabetes; CD4⁺T cells; CD8⁺T cells 28, 161
- Type 1 diabetes**; Quality of life; Coping and defence mechanisms; Retro and prospective longitudinal studies 28, 63
- Vagus nerve**; Gastric emptying; Autonomic neuropathy; Spontaneously diabetic Chinese hamster 28, 89
- Withdrawal of insulin**; Insulin therapy; Non-obese NIDDM; Proliferative retinopathy 28, 119